v3.26.1
Basis of Presentation and Significant Accounting Policies - Summary of Significant Expense Categories Regularly Reviewed CODM (Details) - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Significant Accounting Policies [Line Items]    
Collaboration revenue $ 7,945,753 $ 3,554,061
Research and development expenses:    
Total research and development expenses [1] 16,734,549 11,865,654
General and administrative expenses:    
Employee related costs 3,100,930 2,685,556
Stock-based compensation 2,802,173 1,588,667
Other general and administrative expenses [2] 5,546,363 4,611,534
Total general and administrative expenses 11,449,466 8,885,757
In-process research and development 2,289,602 25,000
Depreciation 27,361 27,361
Other income (1,332,207) (1,648,637)
Pre-tax loss (21,223,018) (15,601,074)
Income tax benefit (3,089) 720,287
Net loss (21,226,107) (14,880,787)
Clinical product candidates    
Research and development expenses:    
Total research and development expenses [1] 4,873,971  
Preclinical product candidates    
Research and development expenses:    
Total research and development expenses [1] 6,509,360 8,313,290
Sponsored research    
Research and development expenses:    
Total research and development expenses [1] 908,928 556,265
Internal research and development expenses, including stock-based compensation    
Research and development expenses:    
Total research and development expenses [1] $ 4,442,290 $ 2,996,099
[1] External research and development expenses include: fees paid to CROs, CMOs and research laboratories, process development, manufacturing and clinical development activities. Any internal research and development expenses associated with clinical product candidates are captioned as internal research and development expenses.
[2] Other general and administrative costs include professional fees, investor relation costs, taxes, licenses, and insurance.